For patients with advanced NSCLC harboring epidermal growth factor receptor (EGFR) gene mutations, which accounts for 30–50% of NSCLC cases in East Asia, the first generation of EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib have superior therapeutic efficacy compared to traditional platinum-based chemotherapy [3, 4] and the median progression-free survival (PFS) is 9–13 months. This evidence concerns the gene EGFR and non-small cell lung carcinoma.